Looking at the various personas a decentralized trial engages with we will look at the barriers to participation/adoption. We will have a call to action from a sponsor, CRO and regulatory space to help continuing to drive decentralized clinical trials.

Speaker:

Emily Mitchell
Executive Director, Decentralised Clinical Trial Solutions
ICON plc

In this presentation, we will explore the origin of Decentralized Clinical Trials. Many believe COVID was the impetus, but DCTs have been utilized in trials long before the pandemic. We'll discuss the impact of COVID-19 on DCTs, the origin of DCTs, and how DCTs are living up to their promise of greater diversity, equity, and inclusion.

By highlighting the potential of DCTs to address DEI challenges in clinical trials, this presentation aims to contribute to ongoing efforts to promote greater diversity, equity, and inclusion in biomedical research and improve the health outcomes of all patient populations.

Speaker:

Kyle Hogan
President
Datacubed Health

• Explore data on the digital readiness of leading pharma sponsors to implement novel trials
• Understand the state of adoption of core decentralized research methods and tools (DCT 1.0)
• Consider the next generation of decentralized clinical trials (DCT 2.0) and potential futures
• DTRA Latest Initiative Release

Speaker:

Craig Lipset
Founder & Advisor, Clinical Innovation Partners
Co-chair of the Decentralized Trials & Research Alliance (DTRA) 

According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than $12B by 2030. Sponsors and CROs are taking lessons learned during current DCTs to develop new strategies that create sustainable, repeatable, and effective clinical conduct.

These new strategies should enable organizations to create and own partnerships, use data from past trials to accelerate the speed of research, and ease the  everyday life for sites and participants.

To realize this experience, organizations must identify their own core competencies, build out strategies with partners, and deploy a unified trial platform that acts as a data steward, data analyzer, and a springboard to deploy core trial solutions such as consent, COAs, sensors and more.

Join us as Medable experts Sam Bavery (VP, Strategy & Growth), Paul O’Malley (Growth & Strategy Lead) and Claire Marsden (SVP, Project Mgmt), discuss how sponsors and CROs can take their trial conduct to the next level to help them achieve their organizational goals.

Speakers:

Paul O’Malley
Growth & Strategy Lead
Medable

Claire Marsden, Ph.D., PMP
SVP, Project Management
Medable

Sam Bavery
Vice President, Strategy and Growth
Medable

The presentation is educational content about alternative sites and the overall general area of novel site networks. Specifics can include modelling them/representing them, considerations for internal stakeholders and sponsors within an organization, industry-level guidance, and general directional suggestions for support. Audience could consider the content to be a “starter pack” of how to get involved, how to engage, and potentially how to seek endorsement, some learnings, and what you should look towards to scale up and operationalize.

Speaker:

Sandeep Bhat
Manager, Digital Engagement and Implementation
Global Clinical Operations GSK

The importance of oncology in pharmaceutical research cannot be underestimated. Globally, there are more than 3,500 active cancer trials, a figure that is expected to grow to 10,000 studies by 2026. However, oncology trials face significant challenges such as slow recruitment, lack of diversity, complex protocols and frequent procedures/treatment modalities—which can burden patients and sponsors heavily.

In this webinar, Dr. Shaalan Beg, MD, MS, Vice President, Oncology, at Science 37, Dr. Robert Daly from Memorial Sloan Kettering Cancer Center, and Dr. Ariel Bourla from Janssen will discuss where we are with Oncology trials now, and how virtual sites can help deliver a patient-friendly and accessible approach to clinical research. Discover real-world examples of how virtual sites are incorporated in Oncology trials today, and how the landscape will change in the years to come.

In this session you will learn:

• New ways to operationalize virtual oncology trials
• How virtual sites help reduce patient burden and improve access
• Where the industry is headed with Oncology

Speaker:

Dr. Shaalan Beg, MD, MS
Vice President, Oncology
Science 37

Robert Daly
Assistant Attending/Thoracic Oncology
Memorial Sloan Kettering Cancer Center

Dr. Ariel Bourla
Senior Director, R&D Data Science and Digital
Janssen

Patient centricity and DCT are spoken so commonly together that it is a prevailing assumption that that two are automatically linked.  But do the offering of DCT components, in and of themselves, make a trial patient centric?  Component functionality, participant personal preference and/or technical savviness, cultural considerations, and numerous other elements, can shape the individual experience very differently within similarly designed, or even the same trial.  Is it possible to achieve quality clinical outcomes, while offering component optionality and flexible trial designs?

This presentation will share some of the Bayer journey into DCT adoption and adaption, focusing on the patient experience.

Speaker:

Karen van Benschoten
Associate Director, DCT Operations Manager, DCT Strategy & Implementation
Bayer Pharmaceuticals